Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01927640 · ClinicalTrials.gov registry record · Early Phase 1
Dexmedetomidine for Reversal of Cocaine's Effects on the Heart
A Early Phase 1 study, sponsored by Cedars-Sinai Medical Center.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 115
- Enrollment target
NCT01927640: Completed Early Phase 1 study, sponsored by Cedars-Sinai Medical Center.
NCT01927640 is a Early Phase 1 study that has completed, run by Cedars-Sinai Medical Center. The registered enrollment target is 115 participants, above the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (117% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01927640, a Early Phase 1 study, has completed, sponsored by Cedars-Sinai Medical Center.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 115 participants
- Enrollment target
Study Summary
This study will use myocardial contrast echocardiography performed during a continuous intravenous infusion of Definity microbubbles (Perflutren lipid microbubbles) to determine if dexmedetomidine (an intravenous central sympatholytic drug) can reverse all the cardiovascular effects of low-dose intranasal cocaine-including vasoconstriction in the coronary microcirculation-both in cocaine-naïve and non-treatment seeking cocaine-addicted subjects.
Primary Outcome
Myocardial perfusion will be measured by myocardial contrast echocardiography after dexmedetomidine administration and compared to baseline. There will be no repeat dosing of dexmedetomidine. No longer term outcomes are measured.
Interventions
- DRUG Dexmedetomidine
- DRUG Normal Saline
- DRUG Intranasal cocaine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 115 participants |
| Start Date | 2013-02-01 |
| Est. Completion | 2014-01-15 |
| Phase | Early Phase 1 |
What the finished NCT01927640 record still lists
NCT01927640 is an interventional study that assigns participants to a tested intervention. The registered 115 participants enrollment target is mid-sized for trials with a published cap, above the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (117% higher).
The record links to 0 conditions, and to 3 interventions - of which Dexmedetomidine is the first listed.
NCT01927640 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01927640 about?
NCT01927640 is a clinical study titled "Dexmedetomidine for Reversal of Cocaine's Effects on the Heart". This study will use myocardial contrast echocardiography performed during a continuous intravenous infusion of Definity microbubbles (Perflutren lipid microbubbles) to determine if dexmedetomidine (an intravenous central sympatholytic drug) can reverse all the cardiovascular effects of low-dose intr...
What is the current status of trial NCT01927640?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 115 participants. The study started on 2013-02-01. Estimated completion is 2014-01-15.
What interventions are being tested in trial NCT01927640?
The interventions under investigation include: Dexmedetomidine (DRUG), Normal Saline (DRUG), Intranasal cocaine (DRUG).
Who is sponsoring clinical trial NCT01927640?
This trial is sponsored by Cedars-Sinai Medical Center, which has 339 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01927640's enrollment target sits among peer trials
115 162nd of 2000 higher than 1,839 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02346929 · 115 participants · NA
Hematoma Block for Distal Radius Fracture
- NCT03394365 · 115 participants · Phase 3
A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and Chemotherapy
- NCT03907475 · 115 participants · Phase 2
Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial
- NCT05086692 · 115 participants · Phase 1
A Beta-only IL-2 ImmunoTherapY Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI